Renovorx to present preclinical research data demonstrating its innovative therapy platform's potential utility for the treatment of bile duct cancer

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the global embolization oncology symposium technologies (gest) 2022, today in new york city. the study demonstrates the potential utility of renovorx's proprietary tran
RNXT Ratings Summary
RNXT Quant Ranking